Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease

<p>Abstract</p> <p>Background</p> <p>Numerous epidemiological studies demonstrate that genetic background modifies the onset and the progression of Alzheimer's disease and related neurodegenerative disorders. The efficacious influence of genetic background on the d...

Full description

Bibliographic Details
Main Authors: Kovacech Branislav, Novak Petr, Zilka Norbert, Stozicka Zuzana, Bugos Ondrej, Novak Michal
Format: Article
Language:English
Published: BMC 2010-10-01
Series:Journal of Neuroinflammation
Online Access:http://www.jneuroinflammation.com/content/7/1/64
_version_ 1818447170807791616
author Kovacech Branislav
Novak Petr
Zilka Norbert
Stozicka Zuzana
Bugos Ondrej
Novak Michal
author_facet Kovacech Branislav
Novak Petr
Zilka Norbert
Stozicka Zuzana
Bugos Ondrej
Novak Michal
author_sort Kovacech Branislav
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Numerous epidemiological studies demonstrate that genetic background modifies the onset and the progression of Alzheimer's disease and related neurodegenerative disorders. The efficacious influence of genetic background on the disease pathway of amyloid beta has been meticulously described in rodent models. Since the impact of genetic modifiers on the neurodegenerative and neuroinflammatory cascade induced by misfolded tau protein is yet to be elucidated, we have addressed the issue by using transgenic lines expressing the same human truncated tau protein in either spontaneously hypertensive rat (SHR) or Wistar-Kyoto (WKY) genetic background.</p> <p>Methods</p> <p>Brains of WKY and SHR transgenic rats in the terminal stage of phenotype and their age-matched non-transgenic littermates were examined by means of immunohistochemistry and unbiased stereology. Basic measures of tau-induced neurodegeneration (load of neurofibrillary tangles) and neuroinflammation (number of Iba1-positive microglia, their activated morphology, and numbers of microglia immunoreactive for MHCII and astrocytes immunoreactive for GFAP) were quantified with an optical fractionator in brain areas affected by neurofibrillary pathology (pons, medulla oblongata). The stereological data were evaluated using two-way ANOVA and Student's t-test.</p> <p>Results</p> <p>Tau neurodegeneration (neurofibrillary tangles (NFTs), axonopathy) and neuroinflammation (microgliosis, astrocytosis) appeared in both WKY and SHR transgenic rats. Although identical levels of transgene expression in both lines were present, terminally-staged WKY transgenic rats displayed significantly lower final NFT loads than their SHR transgenic counterparts. Interestingly, microglial responses showed a striking difference between transgenic lines. Only 1.6% of microglia in SHR transgenic rats expressed MHCII in spite of having a robust phagocytic phenotype, whereas in WKY transgenic rats, 23.2% of microglia expressed MHCII despite displaying a considerably lower extent of transformation into phagocytic phenotype.</p> <p>Conclusions</p> <p>These results show that the immune response represents a pivotal and genetically variable modifying factor that is able to influence vulnerability to neurodegeneration. Therefore, targeted immunomodulation could represent a prospective therapeutic approach to Alzheimer's disease.</p>
first_indexed 2024-12-14T19:59:22Z
format Article
id doaj.art-e2dcecd4b1a94ef287a0d2dfeea44de6
institution Directory Open Access Journal
issn 1742-2094
language English
last_indexed 2024-12-14T19:59:22Z
publishDate 2010-10-01
publisher BMC
record_format Article
series Journal of Neuroinflammation
spelling doaj.art-e2dcecd4b1a94ef287a0d2dfeea44de62022-12-21T22:49:12ZengBMCJournal of Neuroinflammation1742-20942010-10-01716410.1186/1742-2094-7-64Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's diseaseKovacech BranislavNovak PetrZilka NorbertStozicka ZuzanaBugos OndrejNovak Michal<p>Abstract</p> <p>Background</p> <p>Numerous epidemiological studies demonstrate that genetic background modifies the onset and the progression of Alzheimer's disease and related neurodegenerative disorders. The efficacious influence of genetic background on the disease pathway of amyloid beta has been meticulously described in rodent models. Since the impact of genetic modifiers on the neurodegenerative and neuroinflammatory cascade induced by misfolded tau protein is yet to be elucidated, we have addressed the issue by using transgenic lines expressing the same human truncated tau protein in either spontaneously hypertensive rat (SHR) or Wistar-Kyoto (WKY) genetic background.</p> <p>Methods</p> <p>Brains of WKY and SHR transgenic rats in the terminal stage of phenotype and their age-matched non-transgenic littermates were examined by means of immunohistochemistry and unbiased stereology. Basic measures of tau-induced neurodegeneration (load of neurofibrillary tangles) and neuroinflammation (number of Iba1-positive microglia, their activated morphology, and numbers of microglia immunoreactive for MHCII and astrocytes immunoreactive for GFAP) were quantified with an optical fractionator in brain areas affected by neurofibrillary pathology (pons, medulla oblongata). The stereological data were evaluated using two-way ANOVA and Student's t-test.</p> <p>Results</p> <p>Tau neurodegeneration (neurofibrillary tangles (NFTs), axonopathy) and neuroinflammation (microgliosis, astrocytosis) appeared in both WKY and SHR transgenic rats. Although identical levels of transgene expression in both lines were present, terminally-staged WKY transgenic rats displayed significantly lower final NFT loads than their SHR transgenic counterparts. Interestingly, microglial responses showed a striking difference between transgenic lines. Only 1.6% of microglia in SHR transgenic rats expressed MHCII in spite of having a robust phagocytic phenotype, whereas in WKY transgenic rats, 23.2% of microglia expressed MHCII despite displaying a considerably lower extent of transformation into phagocytic phenotype.</p> <p>Conclusions</p> <p>These results show that the immune response represents a pivotal and genetically variable modifying factor that is able to influence vulnerability to neurodegeneration. Therefore, targeted immunomodulation could represent a prospective therapeutic approach to Alzheimer's disease.</p>http://www.jneuroinflammation.com/content/7/1/64
spellingShingle Kovacech Branislav
Novak Petr
Zilka Norbert
Stozicka Zuzana
Bugos Ondrej
Novak Michal
Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease
Journal of Neuroinflammation
title Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease
title_full Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease
title_fullStr Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease
title_full_unstemmed Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease
title_short Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease
title_sort genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy implication for immunomodulatory approach to alzheimer s disease
url http://www.jneuroinflammation.com/content/7/1/64
work_keys_str_mv AT kovacechbranislav geneticbackgroundmodifiesneurodegenerationandneuroinflammationdrivenbymisfoldedhumantauproteininratmodeloftauopathyimplicationforimmunomodulatoryapproachtoalzheimersdisease
AT novakpetr geneticbackgroundmodifiesneurodegenerationandneuroinflammationdrivenbymisfoldedhumantauproteininratmodeloftauopathyimplicationforimmunomodulatoryapproachtoalzheimersdisease
AT zilkanorbert geneticbackgroundmodifiesneurodegenerationandneuroinflammationdrivenbymisfoldedhumantauproteininratmodeloftauopathyimplicationforimmunomodulatoryapproachtoalzheimersdisease
AT stozickazuzana geneticbackgroundmodifiesneurodegenerationandneuroinflammationdrivenbymisfoldedhumantauproteininratmodeloftauopathyimplicationforimmunomodulatoryapproachtoalzheimersdisease
AT bugosondrej geneticbackgroundmodifiesneurodegenerationandneuroinflammationdrivenbymisfoldedhumantauproteininratmodeloftauopathyimplicationforimmunomodulatoryapproachtoalzheimersdisease
AT novakmichal geneticbackgroundmodifiesneurodegenerationandneuroinflammationdrivenbymisfoldedhumantauproteininratmodeloftauopathyimplicationforimmunomodulatoryapproachtoalzheimersdisease